GlassScriptPhysician profile
Jane T Purser
NPI 1376524561
$16,365.04
in general payments reported to CMS, 2019-2025
29 companies · $854 in 2025
The $854 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,226 · 2020: $1,165 · 2021: $340 · 2022: $989 · 2023: $3,172 · 2024: $7,619 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,597 · Consulting Fee: $3,500 · Travel and Lodging: $1,404 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,597.28 |
| Consulting Fee | $3,500.00 |
| Travel and Lodging | $1,403.53 |
| Education | $144.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $5,749.55 | 2019-2025 | Ruconest |
| Genentech USA, INC. | $1,396.92 | 2019-2025 | Xolair |
| Astrazeneca Pharmaceuticals LP | $1,293.43 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $1,179.25 | 2020-2024 | Hyqvia, Cuvitru |
| Csl Behring | $1,028.65 | 2019-2025 | Hizentra, Haegarda |
| Regeneron Healthcare Solutions, INC. | $834.65 | 2019-2024 | Dupixent |
| Biocryst US Sales Co., LLC | $622.88 | 2022-2025 | Orladeyo |
| Genzyme Corporation | $595.21 | 2019-2025 | |
| Glaxosmithkline, LLC. | $535.26 | 2019-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Alk-Abello, INC | $516.83 | 2019-2024 | Odactra, Ragwitek, Grastek |
| Genentech, INC. | $406.63 | 2022-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $308.79 | 2019-2024 | |
| Pfizer INC. | $298.99 | 2019-2025 | |
| Blueprint Medicines Corporation | $249.76 | 2023-2024 | Ayvakit |
| Shire North American Group INC | $229.57 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $188.95 | 2021-2023 | |
| Amgen INC. | $178.01 | 2023-2024 | Tezspire |
| Optinose US, INC. | $169.01 | 2019-2025 | |
| Grifols USA, LLC | $104.20 | 2019 | |
| Kaleo, INC. | $91.53 | 2019-2023 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $70.34 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.03 | 2022-2023 | Spiriva Respimat |
| Mylan Specialty L.P. | $64.43 | 2023-2024 | Yupelri |
| Greer Laboratories, INC. | $58.40 | 2019-2024 | Oralair |
| Galderma Laboratories, L.P. | $48.25 | 2025 | Nemluvio |
| Abbvie INC. | $30.97 | 2022 | |
| Merck Sharp & Dohme LLC | $18.74 | 2023 | |
| Currax Pharmaceuticals LLC | $14.48 | 2024 | Onzetra Xsail |
| Teva Pharmaceuticals USA, INC. | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Purser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.